DKMA Update

11 September 2017

Our newsletter Danish Pharmacovigilance Update changes name to DKMA Update and will from now on contain information about medicinal products in general, patient safety and life science.

DKMA Update is an electronic newsletter intended for anyone who work with medicines, either clinically or in the pharmaceutical industry or the retail industry, and people who would like to gain an insight into our work.

The newsletter will continue to focus on the most recent safety updates, but will also focus on other current pharmaceutical topics.

In this issue, our Director General Thomas Senderovitz presents his view on Brexit’s impact on European pharmaceutical collaboration.

You can also read about:

  • Tramadol subject to stricter reporting
  • Strengthened recommendations to reduce risk of hyponatraemia in use of solutions for infusion
  • New precautions for safe use of the antiepileptic Pro-Epanutin

And you can get an overview of the Danish Medicines Agency's social media presence.

We would appreciate any comments or feedback on DKMA Update that will help us to enhance the format of the newsletter.

Please send your comments to: Send an email


DKMA Update, September 2017 (PDF)

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.